Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells (original) (raw)

Abstract

We present data that retroviral gene expression in early hematopoietic cells is subjected to transcriptional controls similar to those previously described for embryonic stem cells. Transient transfection experiments revealed that both the viral enhancer region in the U3 region of the long terminal repeat as well as a repressor element coincident with the primer binding site of Moloney leukemia viruses are limiting for expression in hematopoietic cells in a differentiation-dependent manner. Within the group of Moloney leukemia virus-related viruses, only the myeloproliferative sarcoma virus showed high enhancer activity in myeloid (including erythroid) cells. In contrast, enhancer regions related to the Friend mink cell focus-forming viruses mediate much higher gene expression levels in both multipotent and lineage-committed myeloid cells. In addition, transcriptional repression related to sequences in the primer binding site of Moloney leukemia virus-derived vectors is also found in early hematopoietic cells and can be overcome by using the corresponding sequences of the murine embryonic stem cell virus. On the basis of these results, two types of novel retroviral hybrid vectors were developed; they combine the U3 regions of either the Friend mink cell focus-forming virus family or the myeloproliferative sarcoma virus with the primer binding site of the murine embryonic stem cell virus. When used to express the human multiple drug resistance gene, these vectors substantially improve protection to cytostatic drugs in transduced hematopoietic cell lines FDC-Pmix, TF-1, and K-562 in comparison with Moloney leukemia virus-derived vectors presently used for the stem cell protection approach in somatic gene therapy.

Full Text

The Full Text of this article is available as a PDF (245.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlers N., Hunt N., Just U., Laker C., Ostertag W., Nowock J. Selectable retrovirus vectors encoding Friend virus gp55 or erythropoietin induce polycythemia with different phenotypic expression and disease progression. J Virol. 1994 Nov;68(11):7235–7243. doi: 10.1128/jvi.68.11.7235-7243.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Akgün E., Ziegler M., Grez M. Determinants of retrovirus gene expression in embryonal carcinoma cells. J Virol. 1991 Jan;65(1):382–388. doi: 10.1128/jvi.65.1.382-388.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arceci R. J., Stieglitz K., Bras J., Schinkel A., Baas F., Croop J. Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. Cancer Res. 1993 Jan 15;53(2):310–317. [PubMed] [Google Scholar]
  4. Asche W., Colletta G., Warnecke G., Nobis P., Pennie S., King R. M., Ostertag W. Lack of retrovirus gene expression in somatic cell hybrids of friend cells and teratocarcinoma cells with a teratocarcinoma phenotype. Mol Cell Biol. 1984 May;4(5):923–930. doi: 10.1128/mcb.4.5.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baum C., Forster P., Hegewisch-Becker S., Harbers K. An optimized electroporation protocol applicable to a wide range of cell lines. Biotechniques. 1994 Dec;17(6):1058–1062. [PubMed] [Google Scholar]
  6. Beck-Engeser G., Stocking C., Just U., Albritton L., Dexter M., Spooncer E., Ostertag W. Retroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and precursor cell lines, but retroviral infection is reduced in more primitive cells. Hum Gene Ther. 1991 Spring;2(1):61–70. doi: 10.1089/hum.1991.2.1-61. [DOI] [PubMed] [Google Scholar]
  7. Challita P. M., Kohn D. B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2567–2571. doi: 10.1073/pnas.91.7.2567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Challita P. M., Skelton D., el-Khoueiry A., Yu X. J., Weinberg K., Kohn D. B. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. 1995 Feb;69(2):748–755. doi: 10.1128/jvi.69.2.748-755.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chaudhary P. M., Roninson I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991 Jul 12;66(1):85–94. doi: 10.1016/0092-8674(91)90141-k. [DOI] [PubMed] [Google Scholar]
  10. Chen C. J., Chin J. E., Ueda K., Clark D. P., Pastan I., Gottesman M. M., Roninson I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986 Nov 7;47(3):381–389. doi: 10.1016/0092-8674(86)90595-7. [DOI] [PubMed] [Google Scholar]
  11. Colicelli J., Goff S. P. Isolation of a recombinant murine leukemia virus utilizing a new primer tRNA. J Virol. 1986 Jan;57(1):37–45. doi: 10.1128/jvi.57.1.37-45.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Friel J., Hughes D., Pragnell I., Stocking C., Laker C., Nowock J., Ostertag W., Padua R. A. The malignant histiocytosis sarcoma virus, a recombinant of Harvey murine sarcoma virus and Friend mink cell focus-forming virus, has acquired myeloid transformation specificity by alterations in the long terminal repeat. J Virol. 1990 Jan;64(1):369–378. doi: 10.1128/jvi.64.1.369-378.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  14. Grez M., Akgün E., Hilberg F., Ostertag W. Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9202–9206. doi: 10.1073/pnas.87.23.9202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Grez M., Zörnig M., Nowock J., Ziegler M. A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells. J Virol. 1991 Sep;65(9):4691–4698. doi: 10.1128/jvi.65.9.4691-4698.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hanania E. G., Deisseroth A. B. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther. 1994 Mar;1(1):21–25. [PubMed] [Google Scholar]
  17. Hawley R. G., Fong A. Z., Burns B. F., Hawley T. S. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J Exp Med. 1992 Oct 1;176(4):1149–1163. doi: 10.1084/jem.176.4.1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hilberg F., Stocking C., Ostertag W., Grez M. Functional analysis of a retroviral host-range mutant: altered long terminal repeat sequences allow expression in embryonal carcinoma cells. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5232–5236. doi: 10.1073/pnas.84.15.5232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kabat D. Molecular biology of Friend viral erythroleukemia. Curr Top Microbiol Immunol. 1989;148:1–42. doi: 10.1007/978-3-642-74700-7_1. [DOI] [PubMed] [Google Scholar]
  20. Kaleko M., Garcia J. V., Osborne W. R., Miller A. D. Expression of human adenosine deaminase in mice after transplantation of genetically-modified bone marrow. Blood. 1990 Apr 15;75(8):1733–1741. [PubMed] [Google Scholar]
  21. Kempler G., Freitag B., Berwin B., Nanassy O., Barklis E. Characterization of the Moloney murine leukemia virus stem cell-specific repressor binding site. Virology. 1993 Apr;193(2):690–699. doi: 10.1006/viro.1993.1177. [DOI] [PubMed] [Google Scholar]
  22. Li Y., Golemis E., Hartley J. W., Hopkins N. Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J Virol. 1987 Mar;61(3):693–700. doi: 10.1128/jvi.61.3.693-700.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Linemeyer D. L., Ruscetti S. K., Menke J. G., Scolnick E. M. Recovery of biologically active spleen focus-forming virus from molecularly cloned spleen focus-forming virus-pBR322 circular DNA by cotransfection with infectious type C retroviral DNA. J Virol. 1980 Sep;35(3):710–721. doi: 10.1128/jvi.35.3.710-721.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Longmore G. D., Pharr P., Neumann D., Lodish H. F. Both megakaryocytopoiesis and erythropoiesis are induced in mice infected with a retrovirus expressing an oncogenic erythropoietin receptor. Blood. 1993 Oct 15;82(8):2386–2395. [PubMed] [Google Scholar]
  25. Ludescher C., Thaler J., Drach D., Drach J., Spitaler M., Gattringer C., Huber H., Hofmann J. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol. 1992 Sep;82(1):161–168. doi: 10.1111/j.1365-2141.1992.tb04608.x. [DOI] [PubMed] [Google Scholar]
  26. McLachlin J. R., Eglitis M. A., Ueda K., Kantoff P. W., Pastan I. H., Anderson W. F., Gottesman M. M. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst. 1990 Aug 1;82(15):1260–1263. doi: 10.1093/jnci/82.15.1260. [DOI] [PubMed] [Google Scholar]
  27. Miller A. D., Miller D. G., Garcia J. V., Lynch C. M. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 1993;217:581–599. doi: 10.1016/0076-6879(93)17090-r. [DOI] [PubMed] [Google Scholar]
  28. Mulligan R. C. The basic science of gene therapy. Science. 1993 May 14;260(5110):926–932. doi: 10.1126/science.8493530. [DOI] [PubMed] [Google Scholar]
  29. Neyfakh A. A. Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res. 1988 Jan;174(1):168–176. doi: 10.1016/0014-4827(88)90152-8. [DOI] [PubMed] [Google Scholar]
  30. Ostertag W., Stocking C., Johnson G. R., Kluge N., Kollek R., Franz T., Hess N. Transforming genes and target cells of murine spleen focus-forming viruses. Adv Cancer Res. 1987;48:193–355. doi: 10.1016/s0065-230x(08)60693-4. [DOI] [PubMed] [Google Scholar]
  31. Pastan I., Gottesman M. M., Ueda K., Lovelace E., Rutherford A. V., Willingham M. C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4486–4490. doi: 10.1073/pnas.85.12.4486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Podda S., Ward M., Himelstein A., Richardson C., de la Flor-Weiss E., Smith L., Gottesman M., Pastan I., Bank A. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9676–9680. doi: 10.1073/pnas.89.20.9676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sorrentino B. P., Brandt S. J., Bodine D., Gottesman M., Pastan I., Cline A., Nienhuis A. W. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science. 1992 Jul 3;257(5066):99–103. doi: 10.1126/science.1352414. [DOI] [PubMed] [Google Scholar]
  34. Speck N. A., Renjifo B., Golemis E., Fredrickson T. N., Hartley J. W., Hopkins N. Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity. Genes Dev. 1990 Feb;4(2):233–242. doi: 10.1101/gad.4.2.233. [DOI] [PubMed] [Google Scholar]
  35. Spiro C., Li J. P., Bestwick R. K., Kabat D. An enhancer sequence instability that diversifies the cell repertoire for expression of a murine leukemia virus. Virology. 1988 Jun;164(2):350–361. doi: 10.1016/0042-6822(88)90548-x. [DOI] [PubMed] [Google Scholar]
  36. Stocking C., Bergholz U., Friel J., Klingler K., Wagener T., Starke C., Kitamura T., Miyajima A., Ostertag W. Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. Growth Factors. 1993;8(3):197–209. doi: 10.3109/08977199309011023. [DOI] [PubMed] [Google Scholar]
  37. Stocking C., Kollek R., Bergholz U., Ostertag W. Long terminal repeat sequences impart hematopoietic transformation properties to the myeloproliferative sarcoma virus. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5746–5750. doi: 10.1073/pnas.82.17.5746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ward M., Richardson C., Pioli P., Smith L., Podda S., Goff S., Hesdorffer C., Bank A. Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood. 1994 Sep 1;84(5):1408–1414. [PubMed] [Google Scholar]
  39. Wolff L., Kaminchik J., Hankins W. D., Ruscetti S. K. Sequence comparisons of the anemia- and polycythemia-inducing strains of Friend spleen focus-forming virus. J Virol. 1985 Feb;53(2):570–578. doi: 10.1128/jvi.53.2.570-578.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wolff L., Scolnick E., Ruscetti S. Envelope gene of the Friend spleen focus-forming virus: deletion and insertions in 3' gp70/p15E-encoding region have resulted in unique features in the primary structure of its protein product. Proc Natl Acad Sci U S A. 1983 Aug;80(15):4718–4722. doi: 10.1073/pnas.80.15.4718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Yamauchi M., Freitag B., Khan C., Berwin B., Barklis E. Stem cell factor binding to retrovirus primer binding site silencers. J Virol. 1995 Feb;69(2):1142–1149. doi: 10.1128/jvi.69.2.1142-1149.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]